MDNA News and Press, Medicenna Therapeutics Corp. From 07/27/21

koto_feja/E+ via Getty Images Medicenna Therapeutics (MDNA) said that the initiation of its Phase 1/2 trial of MDNA11 in patients with advanced solid tumors is on track with enrollment set to start in the third quarter of 2021 in Australia. Shares up nearly 9% premark...

-  Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid tumors - Study to start enrollment in the third quarter of 2021 in Australia, with expansion to additional sites in the US, UK and Canada ...

-- Preclinical results in a pancreatic cancer model show that MDNA109, delivered by an oncolytic adenovirus, induced superior anti-tumor response with tendency towards complete tumor regression, improved survival, and long-term immune memory effect -- The data highlight the abil...

Ocuphire Pharma (OCUP) +71% after Phase 2 VEGA-1 trial in presbyopia meets endpoints.Vertex Energy (VTNR) +43% as Clean Harbors to acquire  certain assets.Verb Technology Company (VERB) +37%.Bridgeline Digital (BLIN) +29%.AST SpaceMobile (ASTS) +22%.Exela Technologies (XELA) +2...

-- Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter of 2021 -- Trial is designed to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors -- Preli...

Stocks continue to rally in 2021. June is the sixth month in a row the TSX Composite Index has reached a fresh record high. Nonetheless, some tiny stocks still look undervalued. Bay Street analysts expect some of these stocks to more than double in the next 12 months. Most of these ...

Medicenna Therapeutics Corp. (MDNA) Q4 2021 Earnings Conference Call May 28, 2021, 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dr. Fahar Merchant - President and CEO Dr. Mann Muhsin - Chief Medical Officer Dr. Kevin Moulder - Chief Scientific Officer Mina Merchant - Chief...

Medicenna Therapeutics (MDNA): FY GAAP EPS of -C$0.35.Cash, cash equivalents, and marketable securities of C$40.4M at March 31, 2021, the funds provide the Company with sufficient capital to execute its current planned expenditures through late 2022 based on its current plans and projections....

-- Management hosting conference call and webcast today at 8:30 AM ET TORONTO and HOUSTON, May 28, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, t...

TORONTO and HOUSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on May 28, 2021 at 8:30 AM ET to ...